We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

101 hedge funds and large institutions have $387M invested in VistaGen Therapeutics in 2021 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 19

71% more capital invested

Capital invested by funds: $227M → $387M (+$160M)

36% more funds holding

Funds holding: 74 → 101 (+27)

5% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 22

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.31% less ownership

Funds ownership: 2.46% → 2.15% (-0.31%)

Holders
101
Holders Change
+27
Holders Change %
+36.49%
% of All Funds
1.76%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
46
Increased
23
Reduced
22
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$22.2M
2
O
OrbiMed
New York
+$14.5M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$7.6M
4
State Street
State Street
Massachusetts
+$7.56M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.88M

Top Sellers

Rank Fund Capital Flow
1
MWNA
Marshall Wace North America
New York
-$6.02M
2
GTC
Ghost Tree Capital
New York
-$5.29M
3
IC
Ikarian Capital
Texas
-$4.86M
4
Millennium Management
Millennium Management
New York
-$3.01M
5
SB
Samsara BioCapital
California
-$2.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
Marshall Wace
101
Marshall Wace
United Kingdom
– -$2.26M -35,408 Closed
ECM
102
ExodusPoint Capital Management
New York
– -$684K -10,702 Closed
HIIFS
103
Harel Insurance Investments & Financial Services
Israel
– -$1.42M -6,667 Closed
HF
104
HRT Financial
New York
– -$356K -5,582 Closed
Capstone Investment Advisors
105
Capstone Investment Advisors
New York
– -$267K -4,172 Closed
LP
106
LMR Partners
United Kingdom
– -$181K -2,826 Closed
VF
107
Virtu Financial
New York
– -$132K -2,071 Closed
JG
108
Jefferies Group
New York
– -$61.6K -963 Closed
FAIM
109
Financial Advocates Investment Management
Washington
– -$49K -770 Closed
NA
110
NewEdge Advisors
Louisiana
– -$47K -743 Closed
AI
111
Atom Investors
Texas
– -$41K -639 Closed
TSS
112
Two Sigma Securities
New York
– -$27K -430 Closed
JMPWA
113
JP Morgan Private Wealth Advisors
California
– -$21K -333 Closed
SM
114
Sciencast Management
New Jersey
– -$21K -333 Closed
IAIM
115
International Assets Investment Management
Florida
– -$6K -92 Closed
NL
116
NVWM LLC
Pennsylvania
– -$2K -33 Closed
Wells Fargo
117
Wells Fargo
California
– -$2K -29 Closed
BC
118
Burleson & Co
California
– -$1K -12 Closed
ASN
119
Advisory Services Network
Georgia
– +$222 +3 New
1 2 3 4
5

VTGN Hedge Fund Activity: Q2 2021 in Review

101 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2021, worth a combined $387M — up 71% from $227M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new VTGN positions and 19 closed out — a net gain of 27 holders — while 23 added to existing stakes and 22 trimmed.

The largest buyer was BlackRock, adding an estimated $22.2M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $6.02M sold.

  • 101 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2021, up from 74 in Q1 2021.
  • Funds reported $387M of VistaGen Therapeutics stock for Q2 2021, up 71% quarter-over-quarter.
  • 46 funds opened new VistaGen Therapeutics positions in Q2 2021 and 19 closed out, a net change of +27 holders.
  • The largest VistaGen Therapeutics buyer in Q2 2021 was BlackRock, an estimated $22.2M added.
  • The largest VistaGen Therapeutics seller in Q2 2021 was Marshall Wace North America, an estimated $6.02M sold.

Based on aggregated 13F filings for Q2 2021.